Table 2 Information of all flares in the entire patient cohort
|  | Total (N = 2377) | RA (n = 1563, 65.8%) | PsA (n = 415, 17.5%) | SpA (n = 399, 16.8%) | p value* |
|---|---|---|---|---|---|
Flare | Â | Â | Â | Â | 0.70 |
 No flare, n (%) | 1857 (78.1) | 1230 (78.7) | 315 (75.9) | 312 (78.2) |  |
 Flare within 3 months from first dose, n (%) | 325 (13.7) | 206 (13.2) | 66 (15.9) | 53 (13.3) |  |
 Flare outside of 3 months from first dose, n (%) | 195 (8.2) | 127 (8.1) | 34 (8.2) | 34 (8.5) |  |
Time from first vaccine dose to flare, months, median (IQR) | 2.1 (1.0–3.9) | 2.0 (1.1–3.9) | 2.1 (0.7–3.7) | 2.2 (1.1–4.2) | 0.37 |
Number of vaccine doses before flare | Â | Â | Â | Â | 0.07 |
 One dose, n (%) | 107 (4.5) | 62 (4.0) | 29 (7.0) | 16 (4.0) |  |
 Two doses, n (%) | 413 (17.4) | 271 (17.3) | 71 (17.1) | 72 (17.8) |  |
COVID-19 vaccine type by patients who flared | Â | Â | Â | Â | 0.04 |
 Pfizer, n (%) | 440 (18.5) | 292 (18.7) | 79 (19.0) | 69 (17.3) |  |
 Moderna, n (%) | 80 (3.4) | 41 (2.6) | 21 (5.1) | 18 (4.5) |  |
Severity of flare | Â | Â | Â | Â | 0.37 |
 Mild and self-limiting, n (%) | 124 (5.2) | 72 (4.6) | 27 (6.5) | 25 (6.3) |  |
 Mild to moderate, non-self-limiting, n (%) | 338 (14.2) | 227 (14.5) | 62 (14.9) | 49 (12.3) |  |
 Severe, n (%) | 58 (2.4) | 34 (2.2) | 11 (2.7) | 13 (3.3) |  |
Flares requiring treatment escalation, n (%) | 362 (15.2) | 248 (15.9) | 64 (15.4) | 50 (12.5) | 0.25 |
Flares requiring hospitalisation, n (%) | 17 (0.7) | 10 (0.6) | 6 (1.4) | 1 (0.3) | 0.16 |